New firm for modified DNA drugs

Flagship Pioneering has launched Serif Biomedicines, a Cambridge startup built around “modified DNA” drugs that aim to last longer than messenger RNA and be easier to repeat than gene therapy. (flagshippioneering.com) Serif came out of Flagship Labs on April 21, 2026, after five years of platform work and with an initial $50 million commitment from Flagship, according to the launch announcement. The company was founded in 2021 and is led by co-founder and chief executive Jacob Rubens. (flagshippioneering.com) (fiercebiotech.com) Genetic medicines work by delivering biological instructions into cells. Messenger RNA gives short-lived instructions in the cell’s outer compartment, while gene therapy usually uses viruses to carry DNA into the nucleus, the cell’s control room, for longer-lasting effects. (biopharmadive.com) (fiercebiotech.com) Serif says its approach uses chemically altered DNA packaged in lipid nanoparticles, plus messenger RNA “co-factors” that help move the DNA into the nucleus and turn on gene expression. The company says the DNA does not alter the cell’s genome and is designed to be redosed after intravenous delivery. (flagshippioneering.com) (fiercebiotech.com) The pitch addresses a long-running problem in the field: foreign DNA can trigger immune defenses, and viral gene therapies can be hard to manufacture and often cannot be given repeatedly. Serif says it tested thousands of DNA modifications before settling on versions that reduced immune activation. (flagshippioneering.com) (fiercebiotech.com) Rubens told Chemical & Engineering News that the company’s DNA therapy is meant to add new genetic code as an episome, a piece of DNA that stays separate from the chromosomes, rather than permanently integrating into the genome. He said circular DNA has worked better than linear DNA in the company’s experiments. (cen.acs.org) Serif has not named its first disease targets or disclosed the exact chemical changes in its DNA constructs. Flagship said the company plans to present preclinical data at an upcoming scientific meeting showing tolerability in non-human primates and sustained gene expression with therapeutic effects after intravenous administration. (flagshippioneering.com) (cen.acs.org) The launch extends Flagship’s pattern of backing platform companies that try to open new drug categories. Flagship says it founded Moderna in 2010 around messenger RNA and founded Tessera Therapeutics in 2018 around “gene writing,” another DNA-based approach that inserts or rewrites sequences in the genome. (moderna.com) (flagshippioneering.com) Serif is making a narrower claim than genome-editing companies: not rewriting a patient’s chromosomes, but delivering DNA instructions that behave more durably than RNA without using the viral machinery common in classic gene therapy. Whether that middle ground holds up will depend on the animal data Serif says it is about to show, and later on human trials. (flagshippioneering.com) (biopharmadive.com)